Regulatory GSK eyes October FDA verdict on chronic hep B drug PharmaphorumGSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.Infectious DiseaseRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaphorum GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October. Infectious Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Merck KGaA and Remepy join forces to develop combo drug-digital therapiesNext: Coultreon banks $125M to support testing of former Galapagos immune drug Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
